Eidos Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Francisco CA United States (2013)
Status: Acquired by Bridge Biotherapeutics, Inc. (2020)

Organization Overview

First Clinical Trial
2017
NCT03294707
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Eidos Therapeutics | Eidos Therapeutics, a BridgeBio company

Active Ingredients

Drugs in Phase 3 Trials (1)

ag10 (8 trials)

Drugs in Phase 2 Trials (1)

ferumoxides (feridex I.V.) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloid Neuropathies (Phase 3)

Amyloid Neuropathies, Familial (Phase 3)

Amyloidosis (Phase 3)

Cardiomyopathies (Phase 3)

Heart Diseases (Phase 3)

Polyneuropathies (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 2